Monitor this situation.

Unsubscribe anytime.

[SITUATION] · [ACTIVE] · [HEALTH]

2 clusters · 2 sources · 19 days · First seen 24 days ago · Last updated 5 days ago

Advancements in lung cancer screening and precision medicine

Overview

Developments in lung cancer screening and precision medicine have focused on genomic analysis and artificial intelligence. In August 2026, Pillar Biosciences, LC-SCRUM-Asia, and LSI Medience Corporation announced a collaboration in Japan to conduct genomic screening for approximately 2,000 patients. This initiative utilizes liquid biopsy technology to analyze circulating cell-free DNA and RNA, providing a minimally invasive method for identifying genomic alterations to support precision oncology.

By September 2026, medical AI firms Coreline Soft and Lunit prepared to present advancements at the World Conference on Lung Cancer in Seoul. Coreline Soft highlighted chest CT-based AI solutions designed to manage large-scale screening challenges, such as tracking nodule changes. Lunit presented research using its ‘Lunit SCOPE IO’ platform to analyze tumor microenvironment characteristics in non-small cell lung cancer, aiming to improve treatment strategies through biomarker identification.

Entities

Seoul National University Hospital · World Conference on Lung Cancer · Lunit

Timeline

5 days ago

[TECHNOLOGY] 2 sources
Medical AI firms to present lung cancer advancements at WCLC 2026
Medical AI firms Coreline Soft and Lunit will present lung cancer screening and precision medicine research at the WCLC 2026 in Seoul, focusing on AI-driven diagnostics and biomarker analysis.
24 days ago

[HEALTH] 2 sources
Pillar Biosciences and partners to launch lung cancer genomic screening in Japan
Pillar Biosciences, LC-SCRUM-Asia, and LSI Medience will collaborate on a two-year project in Japan to perform liquid biopsy genomic screening for 2,000 lung cancer patients starting in August 2026.

Sources

bosa.co.kr · thebionews.net